RNA Stock Risk & Deep Value Analysis
RNA
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on RNA
We analyzed RNA using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RNA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈RNA Performance Overview3yr weekly
Unlock RNA Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
RNA Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Low
About RNA (RNA)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$10.82B
RNA Deep Value Analysis
Compare RNA to Similar Stocks
See how RNA stacks up against related companies in our head-to-head analysis.
RNA Red Flags & Warning Signs
Premium- ⚠
Negative or mixed AOC 1001 Phase 3 data readout
- ⚠
Regulatory delays or outright rejection for AOC 1001
- ⚠
Increased competitive pressure from novel therapies
- ⚠
Significant capital raise leading to substantial dilution
Unlock RNA Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
RNA Financial Health Metrics
Market Cap
$10.82B
RNA Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The AOC platform's unique ability to specifically deliver oligonucleotides to target tissues provides a distinct and durable competitive advantage, protected by strong intellectual property. Continued clinical success and expansion into new indications will further fortify this moat.
RNA Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
RNA Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early May 2026)
- •Clinical trial updates for AOC 1025 and AOC 1044 at medical conferences
Medium-Term (6-18 months)
- •AOC 1001 Phase 3 MARINA-DM1 Topline Data Readout (Mid-Late 2026)
- •AOC 1001 Regulatory Filing (Late 2026 / Early 2027)
- •Initiation of new clinical trials for additional AOC candidates
Long-Term (18+ months)
- •AOC 1001 Commercial Launch (2027-2028, post-approval)
- •Expansion of AOC platform to new therapeutic areas
- •Establishment as a multi-product rare disease leader
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
RNA Bull Case: What Could Go Right
- ✓
Positive topline data from AOC 1001 MARINA-DM1 trial
- ✓
Successful regulatory filing and approval for AOC 1001
- ✓
Continued expansion and clinical progression of pipeline assets
- ✓
Cash burn rate relative to cash runway and potential financing needs
Bull Case Analysis
See what could go right with Premium
Never miss a move on RNA
Create a free account to set price alerts and get notified on Telegram when RNA hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for RNA (RNA)?
As of March 11, 2026, RNA has a DVR Score of 8.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of RNA?
RNA's market capitalization is approximately $10.8B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does RNA use?
RNA is the ticker symbol for RNA. The company trades on the NGM.
What is the risk level for RNA stock?
Our analysis rates RNA's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the RNA DVR analysis updated?
Our AI-powered analysis of RNA is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 11, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.